Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 461 | 44% |
| 2020 | 6 | 398 | 46% |
| 2021 | 5 | 373 | 49% |
| 2022 | 5 | 364 | 51% |
| 2023 | 5 | 351 | 53% |
| 2024 | 3 | 322 | 54% |
| 2025 from claims | – | 350 283–411 | 55% |
| 2026 forecast | – | 356 279–447 | 55% |
| 2027 forecast | – | 360 267–476 | 56% |
| 2028 forecast | – | 365 258–504 | 56% |
| 2029 forecast | – | 370 251–530 | 57% |
| 2030 forecast | – | 374 245–555 | 57% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arizona; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 6 | 979−4.9%/yr | −4.9%/yr | 0.3 | 0% | 1,400 in 2030+6.1%/yr |
| Washington | 3 | 302−6.6%/yr | −6.6%/yr | 0.4 | 0% | 230 in 2030−4.4%/yr |
| Colorado | 0 | 174−6.8%/yr | −6.8%/yr | 0.4 | 0% | 200 in 2030+2.7%/yr |
| Oregon | 0 | 169−9.9%/yr | −9.9%/yr | 0.4 | 0% | 170 in 2030−0.3%/yr |
| Nevada | 0 | 117−8%/yr | −8%/yr | 0.4 | 0% | 100 in 2030−2.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 94 | 10,087−0.8%/yr | −0.8%/yr | 13.02.6× | 100% | 10,200 in 2030+0.2%/yr |
| Peripheral arterial intervention | 38 | 4,850−6.8%/yr | −6.8%/yr | 6.21.3× | 74% | 4,560 in 2030−1%/yr |
| Dialysis access | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.21.1× | 88% | 4,140 in 2030+2%/yr |
| Thrombectomy, IVC filters & venous stents | 11 | 1,180+4.1%/yr | +4.1%/yr | 1.61.4× | 19% | 1,490 in 2030+3.9%/yr |
| Carotid revascularization | 21 | 884−3%/yr | −3%/yr | 1.21.5× | 0% | 1,070 in 2030+3.3%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Terumo leads with 42% of company spending on these surgeons in 2025, −17 pts on 2024.
In 2025, 5 companies reported engagement with Arizona’s surgeons worth $171K in consulting, speaking, meals and travel tied to these products, about $57K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.